Best Rate Direct

JACKSONVILLE, Fla., Jan. 28, 2022 /PRNewswire/ — Black Knight, Inc. (NYSE:BKI), a leading provider of software, data and analytics solutions to the mortgage and consumer loan, real estate and capital markets verticals, today announced the date for the release of its fourth quarter and full-year 2021 earnings and its participation in an upcoming investor conference.

Fourth Quarter and Full-Year 2021 Earnings

Black Knight will release fourth quarter and full-year 2021 earnings before the market opens on February 15, 2022. A conference call to discuss its results will follow at 8:30 a.m. Eastern Time that same day.

Those wishing to participate via the webcast should access the call through Black Knight’s Investor Relations website at https://investor.blackknightinc.com. Those wishing to participate via the telephone may dial in at 877-407-4018 (USA) or 201-689-8471 (International). The conference call replay will be available via webcast through Black Knight’s Investor Relations website. The telephone replay will be available from 11:30 a.m. Eastern Time on February 15, 2022, through February 22, 2022, by dialing 844-512-2921 (USA) or 412-317-6671 (International). The replay passcode will be 13726378.

Upcoming Investor Conference

Kirk Larsen, Black Knight’s executive vice president and chief financial officer, and members of the management team will be participating in the William Blair Tech Innovators Conference on Tuesday, March 15, 2022.  

About Black Knight

Black Knight, Inc. (NYSE:BKI) is an award-winning software, data and analytics company that drives innovation in the mortgage lending and servicing and real estate industries, as well as the capital and secondary markets. Businesses leverage our robust, integrated solutions across the entire homeownership life cycle to help retain existing customers, gain new customers, mitigate risk and operate more effectively.

Our clients rely on our proven, comprehensive, scalable products and our unwavering commitment to delivering superior client support to achieve their strategic goals and better serve their customers. For more information on Black Knight, please visit www.blackknightinc.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/black-knight-announces-fourth-and-full-year-2021-earnings-release-and-conference-call-participating-in-an-upcoming-investor-conference-301470593.html

SOURCE Black Knight, Inc.

BALTIMORE, Jan. 28, 2022 /PRNewswire/ — Transamerica announced today that the company earned a score of 100% from the Human Rights Campaign Foundation on their 2022 Corporate Equality Index (CEI). Transamerica has received a perfect score on the annual benchmarking survey and report—which measures workplace equality for LGBTQ+ employees—since 2017.

“Transamerica has made a strong commitment to inclusion and diversity, and we appreciate being recognized once again by the Human Rights Campaign for our efforts to maintain workplace equality,” said Holly Waters, Chief People, Places & Brand Officer at Transamerica. “At Transamerica, we believe that diversity makes us smarter and more creative. We value the wellbeing of all our employees, and we will continue to make every effort to ensure our LGBTQ+ employees receive our support and that all employees are empowered to bring their authentic selves to work each day. We are proud to be an inclusive organization.”

The CEI applies rigorous criteria to rate major businesses on their corporate policies and practices regarding LGBTQ+ inclusion and workforce protections, including non-discrimination policies, equitable benefits for LGBTQ+ workers and their families, support for an inclusive culture, and corporate social responsibility. Transamerica’s effort to meet all the CEI’s criteria resulted in the 100% ranking and the designation as a Best Place to Work for LGBTQ+ Equality.

“When the Human Rights Campaign Foundation created the Corporate Equality Index 20 years ago, we dreamed that LGBTQ+ workers—from the factory floor to corporate headquarters, in big cities and small towns—could have access to the policies and benefits needed to thrive and live life authentically,” said Jay Brown, Human Rights Campaign Senior Vice President of Programs, Research and Training. “We are proud that the Corporate Equality Index paved the way to that reality for countless LGBTQ+ workers in America and abroad. But there is still more to do, which is why we are raising the bar yet again to create more equitable workplaces and a better tomorrow for LGBTQ+ workers everywhere. Congratulations to Transamerica for achieving the title of ‘best places to work for LGBTQ+ equality’ and working to advance inclusion in the workplace.”

Transamerica supports inclusion through unconscious bias training for employees to promote a respectful workplace, as well as Employee Resource Groups (ERGs), including Transamerica PROUD for LGBTQ+ employees and allies. ERGs, which are open to all employees, host regular events to highlight members’ interests and issues and allow members to provide insight and feedback to the company’s leaders.

Prospective employees can find more information about Transamerica and employment opportunities at careers.transamerica.com. More information on the 2022 Corporate Equality Index, including the full report, can be found at https://www.hrc.org/resources/corporate-equality-index.

About Transamerica  

With a history that dates back more than 100 years, Transamerica is recognized as a leading provider of life insurance, retirement, and investment solutions, serving millions of customers throughout the United States. Recognizing the necessity of health and wellness during peak working life, Transamerica’s dedicated professionals work to help people take the steps necessary to live better today so they can worry less about tomorrow. Transamerica serves nearly every customer segment, providing a broad range of quality life insurance and investment products, individual and group pension plans, as well as asset management services. In 2020, Transamerica fulfilled its promises to customers, paying more than $49 billion in insurance, retirement, and annuity claims and benefits, including return of annuity premiums paid by the customer. Transamerica’s corporate headquarters is located in Baltimore, Maryland, with other major operations in Cedar Rapids, Iowa and Denver, Colorado. Transamerica is part of the Aegon group of companies. Based in the Netherlands, Aegon is a diversified financial services group focused on providing investment, protection, and retirement solutions. For the full year of 2020, Aegon managed over $1.1 trillion in revenue generating investments. For more information, visit www.transamerica.com.

Media inquiries:

Media.Relations@transamerica.com

Hank Williams

(319) 355-7789

Julie Quinlan

(303) 383-5923

View original content to download multimedia:https://www.prnewswire.com/news-releases/transamerica-earns-perfect-score-on-corporate-equality-index-301470294.html

SOURCE TRANSAMERICA

AUSTIN, Texas, Jan. 28, 2022 /PRNewswire-PRWeb/ — Briza, Inc., the creator of an insurance-as-a-service Application Programming Interface (API) connecting insurance distributors with carrier underwriting systems, today announced the successful completion of their 2021 System and Organizational Controls (SOC) 2® Type II examination. The audit, conducted by Sensiba San Filippo, LLP (SSF) affirms that Briza’s practices, procedures, policies, and operations meet the SOC 2 standards for security, reliability, processing integrity, and confidentiality.

“The completion of our SOC 2 examination affirms Briza’s commitment to the security and integrity of our platform,” said Rakesh Taranath, Information Security Manager for Briza. “Briza sees itself as a vital custodian of our partners’ data. As commercial insurance continues its digital evolution, it is crucial to be ever more vigilant to keep this information secure.”

Briza’s SOC 2 Type II examination focused on its ongoing commitment to internal controls over data security and data confidentiality.

Briza’s developer platform gives its constituents access to many products from many top-rated carriers with just a single integration, and the company continues to add new partners’ products every month.

Briza simplifies and accelerates interactions between carriers and developers – the company’s API makes it possible for small businesses to procure insurance instantly. For commercial insurance carriers, Briza quickens time to market, reduces project risk, and gives the carrier broad digital distribution without having to manage hundreds of individual relationships with developers.

About Briza

Briza offers a unified commercial insurance API that enables developers to incorporate instant commercial insurance procurement within a native user experience. Briza does the heavy lifting of managing multiple carrier integrations, enabling developers to access multiple top carriers with just a single integration. With Briza, carriers can more efficiently distribute their products, while agencies can quote, bind, and issue policies in seconds. The company has distribution partnerships with leading insurance companies such as Liberty Mutual, Berkshire Hathaway Guard, Hiscox, CNA, Markel, Acuity, AmTrust, EMPLOYERS, Coterie, and more, as well as national wholesalers and managing general agencies.

For Briza inquiries, please contact:

Kevin Bracken

Head of Growth

kbracken@briza.com

Media Contact

Kevin Bracken, Briza, Inc., +1 5163120693, kbracken@briza.io

Facebook

 

SOURCE Briza, Inc.

NEW YORK, Jan. 28, 2022 /PRNewswire/ — The pandemic remains a major concern around the world. According to recent data published by Johns Hopkins University’s Center for Systems Science and Engineering, more than 5.6 million people have died from the disease worldwide, including over 872,000 Americans. As for vaccination statistics, data from the CDC indicates that about 63.5% of the population in the United States is fully vaccinated against COVID-19. Nevertheless, since Thanksgiving, there have been nearly 84,000 confirmed deaths. The Omicron variant, while less lethal than the previous variants, is still highly contagious and is estimated to account for 99.9% of all new cases in the U.S. as of January. 22nd. Yesterday, over 21 million new weekly cases were reported across the globe, the most recorded since the beginning of the pandemic, according to the World Health Organization. Todos Medical Ltd. (OTC: TOMDF), Pfizer Inc. (NYSE: PFE), Novavax, Inc. (NASDAQ: NVAX), BioNTech SE (NASDAQ: BNTX), Sorrento Therapeutics, Inc. (NASDAQ: SRNE)

As a result of the high numbers of new cases, testing kits are in short supply. According to Anthony S. Fauci, Chief Medical Adviser to President Biden, it is going to be very important “that we get a greater capability of testing, particularly when the demand for testing is so high, with the combination of the Omicron variant itself, as well as the holiday season, where people want to get that extra level of assuredness that they’re protected, even if you are vaccinated and boosted.”

Todos Medical Ltd. (OTCQB: TOMDF) together with its 3CL protease theranostic joint venture partner NLC Pharma Ltd., announced yesterday breaking news regarding, “positive interim data for its Tollovir™ oral antiviral 3CL protease inhibitor Phase 2 clinical trial for the treatment of hospitalized (severe and critical) COVID-19 patients. Tollovir met its primary endpoint of reducing time to clinical improvement as measured by the National Emergency Warning System 2 (NEWS2) and met several key secondary clinical endpoints, including complete reduction in COVID-19 deaths. The Company has now formally closed the Phase 2 clinical trial due to positive interim efficacy data. Lead clinical site Shaare Zedek Medical Center now permits the use of Tollovir™ in hospitalized COVID-19 patients on a compassionate use basis.

The Company will host a conference call at 9:15am Eastern Time. The conference call link is: https://audience.mysequire.com/webinar-view?webinar_id=cd68df03-4911-4ded-a910-ba73d61afeeb.

The Company will also be presenting at Emerging Growth Conference at 3:00pm Eastern Time. The link to the presentation is: https://goto.webcasts.com/starthere.jsp?ei=1526304&tp_key=6e03917339

‘It is extremely exciting to see the validation of Tollovir in a placebo-controlled trial which now allows us to continue on the clinical and regulatory path towards Emergency Use Authorization for the treatment of COVID-19 patients,’ said Dr. Dorit Arad, Founder & CTO of NLC Pharma, Todos Medical’s 3CL science-based joint venture partner. ‘The data produced in this study closely mirrors data we generated in an Observational Clinical study conducted in 2020. The recent emergence of the Omicron variant has been pushing healthcare systems to the brink of collapse. Tollovir could be an incredibly powerful tool to reduce death and stabilize patients faster, thereby reducing their recovery time from this debilitating disease. Tollovir will help flatten the curve by freeing up hospital capacity to see more patients and perform other more routine non-COVID related hospital treatments.’

‘We are extremely pleased with the results from this clinical study in the hospital setting of our dual mechanism antiviral & anti-cytokine oral drug candidate Tollovir,’ said Gerald E. Commissiong, President & CEO of Todos Medical. ‘We have already begun preparing manufacturing for commercial quantities of Tollovir so that we will be able to deliver shipments in jurisdictions where we expect to be granted accelerated Emergency Use Authorization (EUA), and are in the process of fine tuning our proposed Phase 2/3 clinical study protocol for hospitalized COVID-19 patients. The new protocol is the key document that will enable our regulatory team to engage with regulatory bodies worldwide, including US FDA. Our goal is to immediately target EUA in jurisdictions that will require limited additional clinical data. We are also preparing for the development of Tollovir for the treatment of:

1) hospitalized pediatric COVID-19,

2) moderate to severe adult COVID-19 in the outpatient setting,

3) moderate to severe pediatric COVID-19 in the outpatient setting,

4) the treatment of Long COVID in adults and

5) the treatment of Long COVID in the pediatric setting.’…

About Dr. Dorit Arad – Dr. Dorit Arad is a D.C. in physical organic chemistry from the Technion who has more than 25 years of experience in the life science industry as an international researcher, executive and entrepreneur. Dr. Arad is a pioneer in the discovery and development of 3CL protease biology related products and product candidates. Dr. Dorit Arad is an interdisciplinary scientist with expertise in computer assisted drug design, biotechnology, mechanism-based drug design, diagnostics, infectious disease and cancer.”

Pfizer Inc. (NYSE: PFE) reported on January 18th, results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells.  “We specifically designed PAXLOVID to retain its activity across coronaviruses, as well as current variants of concern with predominantly spike protein mutations. Following the clinical findings – showing PAXLOVID reduced risk of hospitalization or death by nearly 90% compared to placebo for high-risk patients when treated within five days of symptom onset – we are encouraged by these initial laboratory findings,” said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. “These data suggest that our oral COVID-19 therapy can be an important and effective tool in our continued battle against this devastating virus and current variants of concern, including the highly transmissible Omicron. We will continue to monitor the treatment’s activity in real-world settings and believe that these in vitro findings will continue to be validated.” 

Novavax, Inc. (NASDAQ: NVAX) announced on January 19th, that Australia’s Therapeutic Goods Administration (TGA) has granted approval for provisional  registration of NVX-CoV2373, Novavax’ COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine will be supplied to Australia under the brand name Nuvaxovid™.  “The grant of provisional registration of Nuvaxovid by the TGA reflects Novavax’ increasing momentum around the globe and represents the first-protein based COVID-19 vaccine authorized for use in Australia,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “While the world continues to grapple with the ever-changing nature of the virus, we look forward to delivering our vaccine to the people of Australia. We would also like to extend our gratitude to the Australian clinical trial participants who contributed so significantly to the development of our vaccine.”

BioNTech SE (NASDAQ: BNTX) and InstaDeep Ltd announced on January 11th, the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2. The Early Warning System (EWS) developed in collaboration by BioNTech and InstaDeep is based on artificial intelligence (AI) calculated immune escape and fitness metrics.  “With the advanced computational methods we have been developing over the past months we can analyse sequence information of the Spike protein and rank new variants according to their predicted immune escape and ACE2 binding score,” said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “Early flagging of potential high-risk variants could be an effective tool to alert researchers, vaccine developers, health authorities and policy makers, thereby providing more time to respond to new variants of concern.”

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) and Sorrento Mexico announced this week that COFEPRIS has given EUA approval to Sorrento Mexico to import, market and distribute COVISTIX tests directly in Mexico. COVISTIX is a sensitive platinum colloid-based lateral-flow rapid antigen test for the detection of SARS-CoV-2 infection, including Omicron and Delta variants of concern. Mexico passed 300,000 test-confirmed coronavirus deaths last week, however, so little testing is done in the country of 126 million that a government review of death certificates puts the real toll at almost 460,000. The virus infection spike was largely responsible for the cancelation of 260 flights between Jan. 6 and Jan. 10, as airline employees got infected and had to isolate, causing staff shortages. “The situation in Mexico is quite serious, and Sorrento and Sorrento Mexico are doing everything we can to increase testing capacity for the people of Mexico,” said Dr. Henry Ji, President and CEO of Sorrento.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has signed a five-month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. FinancialBuzz.com has agreed to fifteen million restricted shares, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:

info@financialbuzz.com

+1-877-601-1879

www.FinancialBuzz.com

 

View original content:https://www.prnewswire.com/news-releases/covid-cases-surge-once-again-amidst-a-lack-of-diagnostic-supplies-301470405.html

SOURCE FinancialBuzz.com

BOSTON, Jan. 28, 2022 /PRNewswire/ — Environmental Impact Acquisition Corporation (“ENVI” or the “Company”) (Nasdaq: ENVI) today announced that it had achieved a quorum for the special meeting of its shareholders to be held on February 1, 2022 (the “Special Meeting”), in connection with its business combination with GreenLight Biosciences Inc. (“GreenLight”), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture.

ENVI’s shareholders who have submitted proxies to date on the proposals included in the Company’s proxy statement/prospectus for the Special Meeting have overwhelmingly voted in support of the business combination and all other proposals to be voted on at the meeting. Accordingly, it is anticipated that the business combination and the other proposals will be approved at the Special Meeting. However, shareholders may change or revoke their proxies before or at the Special Meeting.

The business combination, if approved by ENVI shareholders, is expected to close on February 2, 2022. Upon the closing of the business combination, common stock and warrants of the combined company are expected to begin trading on February 3, 2022, on Nasdaq under the ticker symbol GRNA.

 Environmental Impact Acquisition Corp. Stockholder Vote

Stockholders who own shares of Environmental Impact Acquisition Corp., as of the Record Date should submit their vote promptly and no later than 11:59 p.m. Eastern Time on January 31, 2022. Environmental Impact Acquisition Corp. stockholders who need assistance in completing the proxy card, need additional copies of the proxy materials, or have questions regarding the Special Meeting may contact Environmental Impact Acquisition Corp.’s proxy solicitor, D.F. King & Co., Inc., by telephone toll-free at (866) 620-2535 or collect at (212) 269-5550 or by email at ENVI@dfking.com

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

For more information, visit greenlightbiosciences.com

About Environmental Impact Acquisition Corporation

Environmental Impact Acquisition Corp. is a Special Purpose Acquisition Company. The Company is sponsored by CG Investments Inc. VI, an affiliate of Canaccord Genuity, which manages several investment vehicles.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws with respect to the business of GreenLight Biosciences, Inc. and its proposed transaction with Environmental Impact Acquisition Corp. (“ENVI”), including statements regarding the anticipated benefits and uses of GreenLight’s product candidates, the market opportunities for GreenLight’s product candidates, timing of clinical trials, and the timing of commercial launch of product candidates, and the anticipated business combination with ENVI. These forward-looking statements are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from these forward-looking statements, including but not limited to: the need to obtain regulatory approval for GreenLight’s product candidates; the risk that clinical trials will not demonstrate that GreenLight’s therapeutic product candidates are safe and effective; the risk that GreenLight’s product candidates will have adverse side effects or other unintended consequences, which could impair their marketability; the risk that GreenLight’s product candidates do not satisfy other legal and regulatory requirements for marketability in one or more jurisdictions; the risks of enhanced regulatory scrutiny of mRNA solutions; the risk of significant delays in research, development, testing, clinical trials and regulatory approval; the potential inability to achieve GreenLight’s goals regarding scalability and affordability of its product candidates; the anticipated need for additional capital to achieve GreenLight’s business goals; changes in the industries in which GreenLight operates; changes in laws and regulations affecting the business of GreenLight; the risk that the proposed business combination with ENVI may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities; the failure to satisfy conditions to the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; risks that the proposed transaction disrupts current plans and operations of GreenLight; and the potential inability to implement or achieve business plans, forecasts, and other expectations after the completion of the proposed transaction. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the registration statement on Form S-4 discussed below and other documents filed by ENVI from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither ENVI nor GreenLight gives any assurance that GreenLight or ENVI, or the combined company, will achieve any result described in any forward-looking statement.

Important Information and Where to Find It

ENVI has filed a registration statement on Form S-4 with the SEC, which includes a document that serves as a preliminary proxy statement/prospectus of ENVI, referred to as a proxy statement/prospectus. The registration statement was declared effective by the SEC on January 13, 2022 and the definitive proxy statement/prospectus and other relevant documents have been filed with the SEC and mailed to ENVI’s stockholders as of the Record Date.

This press release does not contain all of the information contained in the final proxy statement/prospectus or other documents filed with the SEC. Before making any voting decision, investors and security holders of ENVI are urged to read the registration statement, the final proxy statement/ prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the registration statement, the final proxy statement/prospectus and all other relevant documents filed with the SEC by ENVI through the website maintained by the SEC at www.sec.gov or by sending a written request to ENVI at: ENVI.Inquiries@cgf.com.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Participants in the Solicitation

ENVI, GreenLight and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ENVI’s shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination are contained in the final proxy statement/prospectus. You may obtain free copies of these documents as described above.

View original content to download multimedia:https://www.prnewswire.com/news-releases/envi-announces-quorum-to-pass-business-combination-with-greenlight-biosciences-and-achievement-of-all-transaction-requirements-following-the-redemption-deadline-301470602.html

SOURCE GreenLight Biosciences, Inc.

• Earnings to be released before market opens on Monday, January 31, 2022

XI’AN, China, Jan. 28, 2022 /PRNewswire/ — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022.

In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay of the call will also be archived on the Company’s website and will be available until the next earnings call.

The call and webcast will be available via:

Pre-registration: https://dpregister.com/sreg/10163664/f14b2a0560

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the operator. Participants may pre-register at any time, up to and including after the time that the call has started.

Those without internet access or unable to pre-register may dial in by calling:

U.S. Toll Free: 1-866-777-2509

International Toll: 1-412-317-5413

To listen to the live webcast or to view the accompanying slides, go to the company’s investor website at https://ir.bnlus.com/. The webcast also can be accessed by using the direct link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=Ha8MzXT9

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company’s website.

About Bon Natural Life Limited

The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the natural, health and personal care market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

View original content:https://www.prnewswire.com/news-releases/bon-natural-life-limited-announces-fy2021-earnings-release-date-and-webcast-301470425.html

SOURCE Bon Natural Life Limited

SAN ANTONIO, Jan. 28, 2022 /PRNewswire/ — The board of directors of Cullen/Frost Bankers, Inc. announced that directors Karen E. Jennings and Ida Clement “Weisie” Steen have notified the board of their decision to retire from the board and not stand for re-election to the board when their terms expire at Cullen/Frost’s annual meeting of shareholders in April.

Jennings joined the Cullen/Frost board in 2001 and serves on the Compensation and Benefits Committee, Corporate Governance and Nominating Committee, and the Risk Committee. Steen joined the Cullen/Frost board in 1996 and serves on the Compensation and Benefits Committee, Corporate Governance and Nominating Committee, and the Technology Committee.

“We’re grateful for the leadership and service provided by Weisie and Karen,” said Phil Green, Cullen/Frost Chairman and CEO. “Their veteran presence has been much appreciated as we have grown over the past two decades, and I want to personally thank them for everything they’ve contributed to our company’s success.”

The board decided to nominate Laurie Baker and Linda Burke Rutherford for election to the board by Cullen/Frost shareholders at the upcoming annual meeting of shareholders in April.

Baker is executive vice president and chief operating officer at Camden Property Trust, a Houston-based publicly traded real estate investment trust. She has been with Camden since 1999 and is responsible for the oversight and strategy of Camden’s portfolio operations and investment funds. Baker has a bachelor of business administration degree in marketing from Sam Houston State University and a master of business administration degree in finance from George Washington University.

Rutherford is executive vice president for people and communications at Dallas-based Southwest Airlines. She has been with Southwest since 1992 and has responsibility over the Communications & Outreach and Culture & Engagement functions as well as People Department (human resources), Southwest Airlines University (training and leadership development) and Diversity, Equity & Inclusion. Rutherford has a bachelor of arts degree in journalism from Texas Tech University.

“We’re glad Laurie and Linda both come from great companies that, like Frost, understand the importance of culture and values in generating shareholder value,” Green said.

About Cullen/Frost:

Cullen/Frost Bankers, Inc. (NYSE: CFR) is a financial holding company, headquartered in San Antonio, with $50.9 billion in assets at Dec. 31, 2021. Frost provides a wide range of banking, investments and insurance services to businesses and individuals across Texas in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley and San Antonio regions. Founded in 1868, Frost has helped clients with their financial needs during three centuries. Additional information is available at www.frostbank.com.

Bill Day

Media Relations

210-220-5427

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cullenfrost-bankers-announces-changes-to-board-of-directors-301470461.html

SOURCE Cullen/Frost Bankers, Inc.

OKLAHOMA CITY, Jan. 28, 2022 /PRNewswire/ — Bank7 Corp. (NASDAQ: BSVN) (“the Company”), the parent company of Oklahoma City-based Bank7 (the “Bank”), today reported unaudited results for the fiscal quarter and year ended December 31, 2021. “2021 was certainly a challenging year, and clearly the pandemic-induced stress was the primary culprit; however, we are pleased to report record profits, even after incurring one-time costs associated with our acquisition of Cornerstone Bank. Our success is largely driven by our outstanding team members who are committed to their jobs and our core fundamentals. We are excited about 2022 and look forward to maximizing shareholder value, while also serving our communities by delivering top-notch banking products and services,” said Thomas L. Travis, President and CEO of the Company.

Three months ended December 31, 2021 compared to three months ended December 31, 2020:

– Net income of $5.7 million compared to $4.7 million, an increase of 20.0%

– Total assets of $1.4 billion compared to $1.0 billion, an increase of 32.8%

– Total deposits of $1.2 billion compared to $905.5 million, an increase of 34.5%

– Earnings per share of $0.63 compared to $0.52, an increase of 20.6%

For the year ended December 31, 2021 compared to the year ended December 31, 2020:

– Net income of $23.2 million compared to $19.3 million, an increase of 20.2%

– Total assets of $1.4 billion compared to $1.0 billion, an increase of 32.8%

– Total deposits of $1.2 billion compared to $905.5 million, an increase of 34.5%

Both the Bank’s and the Company’s capital levels continue to be significantly above the minimum levels required to be designated as “well-capitalized” for regulatory purposes.  On December 31, 2021, the Bank’s Tier 1 leverage ratio, Tier 1 risk based capital ratio, and total risk-based capital ratios were 10.46%, 11.53%, and 12.54%, respectively.  On December 31, 2021, on a consolidated basis, the Company’s Tier 1 leverage ratio, Tier 1 risk based capital ratio, and total risk-based capital ratios were 10.46%, 11.53%, and 12.54%, respectively.  Designation as a well-capitalized institution under regulations does not constitute a recommendation or endorsement by bank regulators.

About Bank7 Corp.

We are Bank7 Corp., a bank holding company headquartered in Oklahoma City, Oklahoma. Through our wholly-owned subsidiary, Bank7, we operate twelve locations in Oklahoma, the Dallas/Fort Worth, Texas metropolitan area and Kansas. We are focused on serving business owners and entrepreneurs by delivering fast, consistent and well-designed loan and deposit products to meet their financing needs. We intend to grow organically by selectively opening additional branches in our target markets as well as pursue strategic acquisitions.

Conference Call

Bank7 Corp. has scheduled a conference call to discuss its first quarter results, which will be broadcast live over the Internet, on Friday, January 28, 2022 at 1:00 p.m. Eastern Time. To participate in the call, dial 1-888-348-6421, or access it live over the Internet at https://www.webcaster4.com/Webcast/Page/2179/44221. For those not able to participate in the live call, an archive of the webcast will be available at https://www.webcaster4.com/Webcast/Page/2179/44221 shortly after the call for 1 year.

Cautionary Statements Regarding Forward-Looking Information

This communication contains a number of forward-looking statements. These forward-looking statements reflect Bank7 Corp.’s current views with respect to, among other things, future events and Bank7 Corp.’s financial performance. Any statements about Bank7 Corp.’s expectations, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “believes,” “can,” “could,” “may,” “predicts,” “potential,” “should,” “will,” “estimate,” “plans,” “projects,” “continuing,” “ongoing,”

“expects,” “intends” and similar words or phrases. Any or all of the forward-looking statements in (or conveyed orally regarding) this presentation may turn out to be inaccurate. The inclusion of or reference to forward-looking information in this presentation should not be regarded as a representation by Bank7 Corp. or any other person that the future plans, estimates or expectations contemplated by Bank7 Corp. will be achieved.

These forward-looking statements are subject to significant uncertainties because they are based upon:  the amount and timing of future changes in interest rates, market behavior, and other economic conditions; future laws, regulations, and accounting principles; changes in regulatory standards and examination policies, and a variety of other matters.  These other matters include, among other things, the impact of COVID-19 on the United States economy and our operations, the direct and indirect effect of economic conditions on interest rates, credit quality, loan demand, liquidity, and monetary and supervisory policies of banking regulators.  Bank7 Corp. has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Bank7 Corp. believes may affect its financial condition, results of operations, business strategy and financial needs. Bank7 Corp.’s actual results could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and assumptions that are difficult to predict. If one or more events related to these or other risks or uncertainties materialize, or if Bank7 Corp.’s underlying assumptions prove to be incorrect, actual results may differ materially from what Bank7 Corp. anticipates. You are cautioned not to place undue reliance on forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made and Bank7 Corp. undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required by law. All forward-looking statements herein are qualified by these cautionary statements.

Contact:

Thomas Travis

President & CEO

(405) 810-8600

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bank7-corp-announces-q4-and-full-year-2021-earnings-301470457.html

SOURCE Bank7 Corp.

DALLAS, Jan. 28, 2022 /PRNewswire/ — MassChallenge, the global network for innovators, announced its expansion into the North Texas market to continue the non-profit’s efforts to make Texas a global destination for innovators by 2025. In partnership with Lyda Hill Philanthropies, the expansion is a part of the future-focused Pegasus Park development, an innovation and social impact hub in Dallas designed to boost local biotech, nonprofit, and corporate innovation.

“The collaborative effort that has gone into this expansion and bringing MassChallenge into the North Texas market is an encouraging step for our innovation community,” said Trey Bowels Cofounder, The DEC Network and Co-Chair of The Dallas Mayor’s Task Force on Innovation and Entrepreneurship. “The biotech and life science industries in the area are experiencing rapid growth, and this is a great time for MassChallenge along with North Texas Founding Partner Lyda Hill Philanthropies, to help convene with emerging entrepreneurs within a centralized hub at Pegasus Park. MassChallenge has a global network and resources coupled with the dynamic ecosystem in the North Texas community to help startups scale and grow their businesses.”

Jon Nordby, Head of Community and Ecosystem at MassChallenge, addressed a group of community leaders at the Launch Event on January 27, 2022 and shared how this expansion and the development of the relationship with Lyda Hill Philanthropies will bolster connections and its presence in the area’s burgeoning biotech industry.

“The North Texas ecosystem is at a unique moment in time to capitalize on an incredible opportunity that’s been building for the past few years. Entrepreneurs from around the world will find that the greater Dallas-Fort Worth region represents compelling and differentiated industries that are welcoming of disruption,” said Nordby. “There is substantial growth in the biotech industry as well as 5G and Human Potential related to sports and security, and the region has a large defense and logistics sector where we can offer innovation expertise. This expansion, for us, realizes our vision of connecting the Texas Triangle and opening doors for startups from around the world who are focused on driving solutions across in these industries, and beyond.”

By establishing a footprint in the region and building community, MassChallenge will ramp up operations attracting early resources to the network and collect relevant data from local business leaders. Over the next 3-5 years, MassChallenge plans to verify industry clusters and transition that work into startups that will have a significant impact on corporate innovation pipelines. Pegasus Park will be home to a MassChallenge early-stage accelerator program with a high percentage of biotech/life science startups. Additional programming including market access events, alumni meetups, industry-specific tracks, and pathways to the MassChallenge HealthTech challenge program will also be supported.  

“Finding bold, long-term solutions from the science innovators that MassChallenge will attract and support in North Texas is more critical than ever,” said Lyda Hill, entrepreneur and founder of Lyda Hill Philanthropies. “Their presence is a signal of our region’s rich history of supporting entrepreneurs and will augment North Texas’ reputation for scientific and medical innovation.”

This expansion announcement brought with it an in-person pitch competition that showcased top entrepreneurs and their startups from the North Texas area. Startups who participated represent healthcare and life sciences industries and are innovating biotechnology, wearables, patented therapies for infants, ADHD solutions, and even health-focused sports drinks. The winners earned a spot in MassChallenge’s 2022 early-stage program and Avsana Labs was named the grand prize winner and walked away with $10,000 in equity-free cash.

Since 2017, MassChallenge has utilized its proven, zero-equity model to develop the Texas ecosystem by connecting startups with mentors, experts, and partners to foster the development of new ideas and emerging innovative solutions.

About MassChallenge 

MassChallenge is the global network for innovators. Headquartered in the United States with seven locations worldwide, MassChallenge equips bold entrepreneurs to disrupt the status quo and to create meaningful change. Since launching in 2009, more than 2,900 startups have participated in a MassChallenge program and non-profit has awarded over $17M in equity-free cash prizes. Learn more about MassChallenge at masschallenge.org. 

About Lyda Hill Philanthropies  

Lyda Hill Philanthropies encompasses the charitable giving for founder Lyda Hill and includes her foundation and personal philanthropy. The organization is committed to funding transformational advances in science and nature, empowering nonprofit organizations and improving the Texas and Colorado communities. Because Miss Hill has a fervent belief that “science is the answer” to many of life’s most challenging issues, she has chosen to donate the entirety of her estate to philanthropy and scientific research.

Media Contact: Abby Mills, abby.mills@rfbinder.com, 212-994-7651

View original content to download multimedia:https://www.prnewswire.com/news-releases/masschallenge-texas-announces-expansion-to-north-texas-301470414.html

SOURCE MassChallenge

SAN ANTONIO, Jan. 28, 2022 /PRNewswire/ — Planet Home Lending, LLC, a national mortgage lender and servicer, has a new team in San Antonio, Texas, led by Aldo Del Giudice (NMLS# 292837) with Benjamin Chairez (NMLS# 2066871) and Roland Mancha (NMLS# 2144306) as mortgage loan originators and Veronica Serrano as loan officer assistant.

This is Planet Home Lending’s sixth team in Texas. The team’s VA loan knowledge helps service members stationed at any of the area’s multiple military installations. The company also has loans for first-time homebuyers, move-up buyers, vacation homebuyers and borrowers who fall outside the standard credit box, including self-employed business owners, retirees, foreign nationals and people with credit challenges.

“Planet Home Lending provides San Antonians with a comprehensive suite of lending solutions, Giudice said. “We ensure every step in the process is covered and every question answered. We believe you should know your options and feel at ease and empowered throughout the home loan process.” 

San Antonio has multiple military bases and is nicknamed the Military City. It is also home to the Department of Defense’s largest medical center. The housing market has consistently been strong in San Antonio, which translates into an increased need for home financing options.

Planet Home Lending also offers the My First Texas Home program, which gives people who have not owned a home in the past three years a zero-interest loan they can use to pay up to 5% of their down payment and closing costs.

In addition to the My First Texas Home program, Planet Home Lending offers six other down payment assistance programs in Texas that offer help with closing costs or down payments.

Along with local expertise, Planet Home Lending offers a personal digital mortgage assistant, Skymore by Planet Home Lending™, which consumers can use to apply to get a home loan from anywhere via their mobile device. Borrowers and real estate agents can track loan progress 24/7, reach out to ask their loan officer questions and submit paperwork electronically, to reduce reliance on paper.

Another way Planet Home Lending supports a healthy environment is through a tree-planting partnership with the National Forest Foundation. In 2021, the company funded the planting of 100,000 trees to help restore national forests.

About Planet Financial Group, LLC

Planet Financial Group, LLC, Tampa, Fla., is the parent of Planet Home Lending, LLC and Planet Management Group, LLC, which also does business under the name Planet Renovation Capital.

About Planet Home Lending, LLC

Planet Home Lending, LLC, is a national mortgage lender and servicer delivering exceptional customer experiences to American homeowners and homebuyers. Offering affordable home loans backed by Fannie Mae, Freddie Mac, VA, FHA, USDA and private funders, it fulfills homeownership dreams for people in 47 states, D.C. and Puerto Rico. Planet Home Lending is an Equal Housing Lender. For more information about Planet Home Lending, LLC, please visit https://planethomelending.com/?utm_source=press-release&utm_medium=web&utm_campaign=phl-pr-SanAntonio-2022-2-DR.

Press Contacts:

View original content to download multimedia:https://www.prnewswire.com/news-releases/planet-home-lending-expands-in-san-antonio-texas-301470420.html

SOURCE Planet Home Lending, LLC